Share Surge

Sellas Life Sciences Group Inc. (NASDAQ:SLS) saw its share price rise 14.83% to $10.53 per share on Thursday after a regulatory filing disclosed amendments to employment and severance agreements for President and CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic. The changes create lump‑sum payments upon a “change of control,” fueling speculation of a potential takeover. Investors linked the filing to the upcoming release of the Phase 3 REGAL study results for the company’s acute myeloid leukemia (AML) therapy, expected to be announced once the study reaches its pre‑determined 80th‑patient milestone. As of the last month, 78 patient deaths had been reported, heightening scrutiny of any clinical improvement.